BMS-Pfizer Alliance to unveil real-world data analyses - cost, safety and comparative effectiveness findings associated with oral anticoagulants in non-valvular atrial fibrillation

Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) plan to release real-world data (RWD) analyses of outcomes associated with direct oral anticoagulants (DOAC) among non-valvular atrial fibrillation (NVAF) patients using the U.S. Medicare database - the nation's largest insurer handling more than one billion total claims per year(1)
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news